期刊文献+

普罗布考、厄贝沙坦对自发性高血压大鼠糖代谢及血清脂联素的影响 被引量:4

Effect of probucol and irbesartan,alone and in combination,on glycometabolism and serum adiponectin of spontaneously hypertensive rat
原文传递
导出
摘要 目的探讨抗氧化剂普罗布考、血管紧张素Ⅱ1型受体拮抗剂(AT1R)厄贝沙坦对自发性高血压大鼠(SHR)胰岛素抵抗及血清脂联素的影响。方法 SHR40只随机分为4组,对照组(n=10)、普罗布考组[61mg/(kg.d),n=10]、厄贝沙坦组[50mg/(kg.d),n=10]、联合用药组(普罗布考+厄贝沙坦,n=10);另设同种系雄性WKY大鼠为对照(n=5)。采用灌胃法给药12周,给药结束后,用生化方法测定糖代谢指标,ELISA方法测定血清脂联素含量。结果 SHR和WKY大鼠空腹血糖水平未见明显差异,SHR空腹胰岛素水平高于WKY组[对照组(15.03±3.72)比(11.31±2.53)mU/L;普罗布考组(16.40±3.64)比(11.31±2.53)mU/L;厄贝沙坦组(15.09±3.08)比(11.31±2.53)mU/L;联合用药组(14.34±3.07)比(11.31±2.53)mU/L),均P<0.05]。SHR之间空腹胰岛素水平差异无统计学意义;OGTT结果显示普罗布考组及对照组大鼠30min血糖水平[(12.23±0.71)比(10.52±0.87)mmol/L;(12.57±1.00)比(10.52±0.87)mmol/L,均P<0.01]、120min血糖水平[(8.72±1.18)比(7.28±0.89)mmol/L;(8.78±1.29)比(7.28±0.89)mmol/L,均P<0.01]高于厄贝沙坦组;普罗布考组、厄贝沙坦组及联合用药组脂联素水平高于对照组[(36.58±10.84)比(22.42±2.55)mg/L;(37.54±11.27)比(22.42±2.55)mg/L;(38.47±2.86)比(22.42±2.55)mg/L,均P<0.05]。结论普罗布考及厄贝沙坦可升高SHR血清脂联素水平,厄贝沙坦可降低SHR餐后30、120min血糖水平。 Objective To investigate the effect of probucol and irbesartan on insulin resistance and serum adiponectin of spontaneously hypertensive rat(SHR).Methods Fourty SHR were divided into four groups and treated with placebo(SHR-C group),probucol[61mg/(kg.d)(SHR-pro group),irbesartan[50mg/(kg.d)](SHR-Irb group),or both drugs(SHR-Pro+Irb group)by gavaging for 12weeks.Glycometabolism were measured by biochemistry methods.Serum insulin level were measured by radio-immunity methods.Change of serum adiponectin were measured by ELISA.Results No difference of fasting blood glucose in different groups(P0.05).Serum insulin level of four SHR groups were higher than that of WKY group[SHR-C(15.03±3.72)vs(11.31± 2.53)mU/L;SHR-pro(16.40±3.64)vs(11.31±2.53)mU/L;SHR-Irb(15.09±3.08)vs(11.31±2.53)mU/L;HR-pro+Irb(14.34±3.07)vs(11.31±2.53)mU/L,all P0.05].No difference of serum insulin level in the four SHR groups(P0.05);the result of OGTT showed blood glucose level of SHR-pro,SHR-C group at 30min [(12.23±0.71)vs(10.52±0.87)mmol/L;(12.57±1.00)vs(10.52±0.87)mmol/L,all P0.01],120min [(8.72±1.18)vs(7.28±0.89)mmol/L;(8.78±1.29)vs(7.28±0.89)mmol/L,all P0.01]were higher than that of SHR-Irb group;Serum adiponectin level of SHR-Pro,SHR-Irb,SHR-pro+Irb groups were higher than that of SHR-C group[(36.58±10.84)vs(22.42±2.55)mg/L;(37.54±11.27)vs(22.42±2.55)mg/L;(38.47±2.86) vs(22.42±2.55)mg/L,all P0.05].Conclusion Probucol and irbesartan increased serum adiponectin level of SHR,and Irbesartan decreased blood glucose level at 30and 120min.
出处 《中华高血压杂志》 CAS CSCD 北大核心 2011年第12期1154-1157,共4页 Chinese Journal of Hypertension
关键词 普罗布考 厄贝沙坦 胰岛素抵抗 脂联素 Probucol Irbesartan Insulin resistance Adiponectin
  • 相关文献

参考文献11

  • 1杨宁,赵旭燕,董彦,姜铁民,李玉明.普罗布考、厄贝沙坦对自发性高血压大鼠血压及血清纤溶酶原激活物抑制物1的影响[J].中华高血压杂志,2010,18(6):555-558. 被引量:6
  • 2Dorte X G,Anker J H,Michael W,et al.Plasma calcitonin gene-related peptide is increased prior to obesity,and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats[J].Eur J Endocrinol,2005,153(12):963969.
  • 3Andrei I O,George B,Anthony N,et al.Free fatty acid-induced reduction in glucose-stimulated insulin secretion:Evidence for a role of oxidative stress in vitro and in vivo[J].Diabetes,2007,56(12):2927-2937.
  • 4Chen YW,Huang CF,Keh ST,et al.The role of phosphoinositide3-kinase/Akt signaling in low-dose mercury-induced mouse pancreaticβ-cell dysfunction in vitro and in vivo[J].Diabetes,2006,55(6):1614-1624.
  • 5Praveen KV,Karen EI,Jinah C,et al.Glutathione suppresses TGF-β-induced PAI-1expression by inhibiting p38and JNK MAPK and the binding of AP-1,SP-1,and Smad to the PAI-1promoter[J].Am J Physiol Lung Cell Mol Physiol,2007,293(5):L1281-L1292.
  • 6Zhou MS,Schulman IH,Raij L.Role of angiotensinⅡand oxidative stress in vascular insulin resistance linked to hypertension[J].Am J Physiol Heart Circ Physiol,2009,296(3):H833-839.
  • 7Claudia M,Vincenzo T,Alessandro D.Genetic influences of adiponectin on insulin resistance,type2diabetes,and cardiovascular disease[J].Diabetes,2007,56(5):1198-1209.
  • 8Kwang KK,Michael JQ,Seung HH,et al.Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients[J].Diabetes Care,2006,29(2):195-201.
  • 9Schupp M,Janke J,Clasen R,et al.Angiotensin type1receptorblockers induce peroxisome proliferatoractivated receptor-γactivity[J].Circulation,2004,109(17):2054-2057.
  • 10Hattori Y,Akimoto K,Gross SS,et al.Angiotensin-Ⅱinduced oxidative stress elicits hypoadiponectinaemia in rats[J].Diabetologia,2005,48(6):1066-1074.

二级参考文献12

  • 1周希,李法琦,余江恒,苟晓燕,史若飞.替米沙坦对高血压大鼠纤溶功能的作用机制[J].中华高血压杂志,2006,14(8):651-655. 被引量:13
  • 2Hermann TS, Li W, Dominguez H, et al. Quinapril treatment increases insulin- stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2006,91 (3) : 1001-1008.
  • 3Fortufio A, Jose GS, Moreno MU, etal. Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome[J]. Diabetes, 2006,55 ( 1 ) : 209-215.
  • 4Iturbe BR, Zhan CD, Quiroz Y, et al. Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats [J]. Hypertension, 2003,41 ( 2 ) :341- 346.
  • 5Zhou MS, Schulman IH, Raij L. The role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension[J]. Am J Physiol Heart Circ Physiol, 2009,296 (3) : H833- 839.
  • 6Szasz T, Thakali K, Fink GD, et al. Watts. A Comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease[J]. Exp Bio Med,2007,232(1) :27-37.
  • 7Tan ZY, Lu YJ, Carol A, et al. Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR[J]. Circ Res, 2010,106(11) 536-545.
  • 8Devaraj S, Xu DY, Jialal I. C-Reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells[J]. Circulation, 2003,107 ( 3 ) : 398-404.
  • 9Kunieda Y, Nakagawa K, Nishimura H, et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen aetivator inhibitor-1 induced by angiotensin II in culturedrat aortic endothelial cells[J]. Thromb Res, 2003, 110 (4) 227- 234.
  • 10Alessi MC, Vague IJ. PAI-1 and the metabolic syndrome; links, causes, and consequences[J]. Arterioseler Thromb Vase Biol, 2006,26(10) :2200- 2207.

共引文献5

同被引文献69

  • 1Iwashima Y,Katsuya T,Ishikawa K,et al.Hypoadiponectinemia isan independent risk factor for hypertension[J].Hypertension,2004,43(6):1318-1324.
  • 2Adamczak M,Wiecek A,Funahashi T,et al.Decreased plasma adi-ponectin concentration in patients with essential hypertension[J].Am J Hypertens,2003,16(1):72-77.
  • 3Menzaghi C,Trischitta V,Doria A.Genetic influences of adiponec-tin on insulin resistance,type 2 diabetes,and cardiovascular dis-ease[J].Diabetes,2007,56(5):1198-1209.
  • 4Motoshima H,Wu X,Mahadev K,et al.Adiponectin suppresses prolif-eration and superoxide generation and enhances eNOS activity inendothelial cells treated with oxidized LDL[J].Biochem BiophysRes Commun,2004,315(2):264-270.
  • 5Ouchi N,Ohishi M,Kihara S,et al.Association of hypoadipone-ctinemia with impaired vasoreactivity[J].Hypertension,2003,42(3):231-236.
  • 6Spencer M,Unal R,Zhu B,et al.Adipose tissue extracellular ma-trix and vascular abnormalities in obesity and insulin resistance[J].J Clin Endocrinol Metab,2011,96(12):1990-1998.
  • 7de Mello V D,Schwab U,Kolehmainen M,et al.A diet high infatty fish,bilberries and wholegrain products improves markers ofendothelial function and inflammation in individuals with im-paired glucose metabolism in a randomised controlled trial:thesysdimet study[J].Diabetologia,2011,54(11):2755-2767.
  • 8Verma S,Kuliszewski M A,Li S H,et al.C-reactive protein atten-uates endothelial progemtor cell survival,differentiation,and func-tion:further evidence of a mechanistic link between CRP and car-diovascular disease[J].Circulation,2004,109(17):2058-2067.
  • 9Robinson J G,Ballantyne C M,Hsueh W,et al.Achievement of spec-ified low-density lipoprotein cholesterol,non-high-density lipopro-tein cholesterol apolipoprotein B,and high-sensitivity C-reactiveprotein levels with ezetimibe/simvastatin or atorvastatin in meta-bolic syndrome patients with and without atherosclerotic vasculardisease(from the VYMET study)[J].J Clin Lipidol,2011,5(6):474-482.
  • 10Mouquel F,Guillerel E,Susen S,et al.Metabolic syndrom andcollateral vessel formation inpatients with documented occuludedcoronary arteries:association with hyperglycaemia insulin re-sisitence adiponectin and plasminogen activator inhibitor-1[J].Eur Heart J,2009,30(7):840-849.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部